Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. smalldrugrheuma

SmallDrugRheuma SIGNED

Discovery of Immune Therapeutic Targets and Immunomodulators for the Development of Novel Therapies in Rheumatoid Arthritis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SmallDrugRheuma project word cloud

Explore the words cloud of the SmallDrugRheuma project. It provides you a very rough idea of what is the project "SmallDrugRheuma" about.

molecules    competitiveness    umbrella    frequent    place    edge    cutting    career    drugs    integrate    elucidation    counterbalancing    repurposing    joint    arthropathies    prevent    cas9    mechanism    partnership    originality    3    boosting    quality    tested    disabling    exist    auto    screening    treatment    library    inflammatory    ultimately    prevalence    productive    employed    vivo    mechanisms    compounds    chemoproteomics    progress    immunotherapy    therapies    rheumatoid    altered    adulthood    modulation    deformity    rnaseq    striking    cancer    1    interdisciplinary    public    modulate    immunology    immune    ex    cardiovascular    translated    ra    immunotherapeutics    arthritis    action    technologies    characterizes    possibilities    researcher    treat    chronic    swelling    therapeutic    proof    environment    patients    small    joints    percentage    cell    diseases    containing    company    private    expertise    extensive    utility    cells    inflammation    chemical    candidates    disease    pharmaceutical    libraries    of    effort    approved    pain    multiple    autoimmune    crispr    potentially   

Project "SmallDrugRheuma" data sheet

The following table provides information about the project.

Coordinator		 UNIVERSIDAD DE SANTIAGO DE COMPOSTELA 

Organization address
address: COLEXIO DE SAN XEROME PRAZA DO OBRADOIRO S/N
city: SANTIAGO DE COMPOSTELA
postcode: 15782
website: http://www.usc.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-06-29   to  2020-06-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD DE SANTIAGO DE COMPOSTELA ES (SANTIAGO DE COMPOSTELA) coordinator 170˙121.00

Map

 Project objective

Rheumatoid Arthritis (RA) is an autoimmune chronic disease, characterized by inflammation in multiple joints, ultimately leading to joint deformity, pain and swelling. RA is one of the most frequent inflammatory arthropathies, with a prevalence of 0.3%-1%, striking during the most productive years of adulthood, and is a chronic disabling condition. No therapies exist to prevent RA, and a high percentage of patients do not respond to currently available therapies. Our research aims to integrate expertise on immunology and cutting-edge screening technologies to identify novel immunotherapeutics for RA based on immune modulation mechanisms. The project makes use of an extensive screening effort using a chemical library (60,000 compounds) containing repurposing drugs (drugs already approved for their use for the treatment of other diseases), targeted libraries and lead-like compounds. The aim of the project is to identify novel small molecules capable to modulate the immune response, counterbalancing the altered inflammatory environment that characterizes RA. Elucidation of the mechanism of action of the candidates (cell type, pathway and target) will take place through state-of-the art technologies such as chemoproteomics, RNASeq or CRISPR/Cas9. Ultimately, the most promising candidates will be tested ex vivo in cells from RA patients, providing a proof-of-concept of the therapeutic utility of the identified mechanism. The project is interdisciplinary and will make progress beyond the state of the art, as the identified immunotherapeutics could also be employed to treat other (auto)immune diseases, as well as being potentially translated to immunotherapy of cancer and cardiovascular diseases. The high-quality and originality of this proposal will open up the best career possibilities for the experienced researcher, and will be carried out under the umbrella of a public-private partnership with a pharmaceutical company, boosting European competitiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMALLDRUGRHEUMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMALLDRUGRHEUMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

CODer (2020)

The molecular basis and genetic control of local gene co-expression and its impact in human disease

Read More